^
    2years
    SOPHiA GENETICS and REALM IDx sign letter of intent to collaborate in accelerating cancer research (SOPHiA GENETICS Press Release)
    "SOPHiA GENETICS...and REALM IDx announced today that they signed a letter of intent to collaborate in the co-development of novel genomic applications and commercialization of multi-modal applications. Together, the companies aim to expand next-generation sequencing (NGS) research for cancer care and develop new multi-modal data streams to improve patient outcomes...Assessments can leverage TumorNEXT-HRD, a product of Ambry Genetics, a subsidiary of REALM IDx. SOPHiA GENETICS and REALM IDx also expect to explore the potential for increasing diagnostic insights by combining Ambry Genetics’ Variant Assessment database (AVA) with SOPHiA GENETICS’ SOPHiA DDM (Data-Driven Medicine) platform for HRD detection."
    Licensing / partnership
    |
    TumorNext-HRD